PDCD1 and ovarian cancer: Another study investigated immunogenomic profile in predicting combination treatment response of a PARP inhibitor (PARPi) and an anti-PD-1 antibody in ovarian cancer patients; the authors found two determinants associated with a positive response: mutational signature of defective homologous recombination DNA repair and exhausted CD8+ T cell primed by IFN in the TME.